Companies / South Korea
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Should CJ Corp Decouple Its Pharma Division?
March 2007 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
CJ Corp is one of South Korea's conglomerates - or Chaebol - with operations in diverse fields such as food, entertainment, logistics and pharmaceuticals. The firm wants to become the leading research-based drugmaker in South Korea and has targeted biopharmaceuticals as a premier growth opportunity. BMI investigates whether the division should be decoupled from the parent